JPS59501110A - 抗腫瘍活性を有する薬剤組成物 - Google Patents
抗腫瘍活性を有する薬剤組成物Info
- Publication number
- JPS59501110A JPS59501110A JP57503491A JP50349182A JPS59501110A JP S59501110 A JPS59501110 A JP S59501110A JP 57503491 A JP57503491 A JP 57503491A JP 50349182 A JP50349182 A JP 50349182A JP S59501110 A JPS59501110 A JP S59501110A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tumor
- cancer
- cells
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 26
- 230000000259 anti-tumor effect Effects 0.000 title claims description 10
- 239000000243 solution Substances 0.000 claims description 12
- -1 polyhexamethylene guanidine phosphate Polymers 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 description 21
- 239000000203 mixture Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- 229920002873 Polyethylenimine Polymers 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000006819 RNA synthesis Effects 0.000 description 3
- 208000001792 Sarcoma 37 Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000235 effect on cancer Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- KLZMUJRJFXYDCW-UHFFFAOYSA-N 2-[6-(diaminomethylideneamino)hexyl]guanidine;hydrochloride Chemical compound Cl.NC(N)=NCCCCCCN=C(N)N KLZMUJRJFXYDCW-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1982/000020 WO1984000105A1 (fr) | 1982-06-21 | 1982-06-21 | Preparation medicinale ayant un effet antitumoral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS59501110A true JPS59501110A (ja) | 1984-06-28 |
Family
ID=21616776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57503491A Pending JPS59501110A (ja) | 1982-06-21 | 1982-06-21 | 抗腫瘍活性を有する薬剤組成物 |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59501110A (enExample) |
| CA (1) | CA1194802A (enExample) |
| CH (1) | CH660964A5 (enExample) |
| DE (1) | DE3249514T1 (enExample) |
| FR (1) | FR2535609A1 (enExample) |
| GB (1) | GB2134783B (enExample) |
| NL (1) | NL8220420A (enExample) |
| SE (1) | SE8400453L (enExample) |
| WO (1) | WO1984000105A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001181115A (ja) * | 1999-12-24 | 2001-07-03 | Sk Corp | 殺菌組成物及びその使用方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| DE19628641C2 (de) * | 1996-07-16 | 1998-12-17 | Fresenius Ag | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
| RU2144024C1 (ru) * | 1998-10-28 | 2000-01-10 | Иркутский институт химии СО РАН | Способ получения фосфата полигексаметиленгуанидина |
| KR100557559B1 (ko) * | 1999-12-20 | 2006-03-03 | 에스케이 주식회사 | 폴리헥사메틸렌구아니딘 인산염 분말, 이의 제조방법 및이를 함유한 항균수지 |
| AT505312A1 (de) | 2007-05-15 | 2008-12-15 | Recticel Schlafkomfort Gmbh Sc | Polyurethan-werkstoff mit einer bioziden ausrüstung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3824288A (en) * | 1961-06-09 | 1974-07-16 | Hoffmann La Roche | Substituted hydrazine derivatives and process for the manufacture thereof |
| BR6457241D0 (pt) * | 1963-12-23 | 1973-06-26 | Rohm & Haas | Processo para a preparacao de t-octil-guanidinas |
| GB1492678A (en) * | 1975-08-11 | 1977-11-23 | Ici Ltd | Guanidine derivatives |
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
-
1982
- 1982-06-21 DE DE19823249514 patent/DE3249514T1/de not_active Withdrawn
- 1982-06-21 JP JP57503491A patent/JPS59501110A/ja active Pending
- 1982-06-21 CH CH90284A patent/CH660964A5/de not_active IP Right Cessation
- 1982-06-21 GB GB08403257A patent/GB2134783B/en not_active Expired
- 1982-06-21 NL NL8220420A patent/NL8220420A/nl not_active Application Discontinuation
- 1982-06-21 WO PCT/SU1982/000020 patent/WO1984000105A1/ru not_active Ceased
- 1982-10-07 CA CA000413032A patent/CA1194802A/en not_active Expired
- 1982-11-04 FR FR8218494A patent/FR2535609A1/fr active Granted
-
1984
- 1984-01-30 SE SE8400453A patent/SE8400453L/ not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001181115A (ja) * | 1999-12-24 | 2001-07-03 | Sk Corp | 殺菌組成物及びその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| SE437931B (sv) | 1985-03-25 |
| CA1194802A (en) | 1985-10-08 |
| GB2134783B (en) | 1985-10-30 |
| GB2134783A (en) | 1984-08-22 |
| DE3249514T1 (de) | 1984-05-17 |
| WO1984000105A1 (fr) | 1984-01-19 |
| SE8400453L (sv) | 1985-03-25 |
| SE8400453D0 (sv) | 1984-01-30 |
| CH660964A5 (de) | 1987-06-30 |
| GB8403257D0 (en) | 1984-03-14 |
| FR2535609A1 (fr) | 1984-05-11 |
| NL8220420A (nl) | 1984-05-01 |
| FR2535609B1 (enExample) | 1985-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111909155B (zh) | 蛋白水解靶向嵌合体、提高其口服生物利用度的前药分子及应用 | |
| CN113143965A (zh) | 一种抑制肿瘤增殖的氨基富勒烯材料 | |
| KR100876343B1 (ko) | 항종양제 및 그 제조 방법 | |
| US20070207993A1 (en) | Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases | |
| JPS59501110A (ja) | 抗腫瘍活性を有する薬剤組成物 | |
| EP2448588A1 (fr) | Methodes et compositions pour le traitement de cancers | |
| RU2120939C1 (ru) | 6-[x-(2-гидроксиэтил)аминоалкил]-5,11-диоксо-5,6-дигидро-11h-инде- но/1,2-с/изохинолины или их соли с неорганическими и органическими кислотами, способы их получения и фармацевтическая композиция на их основе | |
| AU2003298077A1 (en) | Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours | |
| CN110183504B (zh) | 一种具有肿瘤靶向性的吉西他滨前体药物及其制备方法和用途 | |
| WO2013123745A1 (zh) | 齐多夫定喹啉共轭化合物及其制备方法和抗肝癌之应用 | |
| US7732485B2 (en) | Treatment of cancer | |
| JPH0572903B2 (enExample) | ||
| CN102532192B (zh) | 一种对乙酰氨基酚—磷酰氮芥抗肿瘤药物及其制备方法 | |
| CN112266396B (zh) | 一种基于生物正交化学的整合型前药、制备方法及其医药用途 | |
| TWI308569B (en) | Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents | |
| JPS62919B2 (enExample) | ||
| CN116139115A (zh) | 厚朴酚和/或和厚朴酚芳环氨基取代类衍生物的抗低氧/缺氧损伤用途及药物组合物 | |
| JP2528370B2 (ja) | 抗腫瘍剤 | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| US4481201A (en) | Pharmaceutical composition containing N,N3 -di-(β-bromopropionyl)-N1,N2 -dispirotripiperazinium dichloride | |
| CN106146612B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
| KR102462782B1 (ko) | 환원반응성 일산화질소 공여 화합물 및 전달체 시스템 | |
| JPS59222417A (ja) | Ｎ，Ｎ−ジエチル−５−メチル−２Ｈ−１−ベンゾチオピラノ−〔４，３，２−ｃｄ〕−インダゾ−ル−２−エタナミン組成物 | |
| TWI245635B (en) | Prodrug comprising vitamin k3 and polymers and method of preparing the same | |
| CN113527266A (zh) | 一种靶向fap的双氧水响应的前药及其制备方法与应用 |